IC
BBIO icon

Ikarian Capital’s BridgeBio Pharma BBIO Stock Holding History

Ikarian Capital’s Portfolio BBIO Stock Details BBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-150,000
Closed -$2.58M – 149
2023
Q2 		$2.58M Buy
+150,000
New +$2.26M 0.41% 56
2022
Q1 		– Sell
-909,700
Closed -$15.2M – 202
2021
Q4 		$15.2M Buy
+909,700
New +$38.5M 2.26% 11

Other funds holding BBIO

JT
Jupiter Topco New York $245B AUM
KKRC
Kohlberg Kravis Roberts & Co New York $5.71B AUM 72.37% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
ACM
Aisling Capital Management New York $472M AUM 106.83% 1-Year Est. Return

Ikarian Capital's BBIO Position: Q2 2026 in Review

Ikarian Capital reduced its BridgeBio Pharma (BBIO) stake by 64% in Q2 2026, selling an estimated $7.19M and leaving 57,417 shares worth $4.28M. The position accounts for 0.46% of the portfolio, ranked #62.

Ikarian Capital first reported a position in BBIO in Q1 2020 and has held it in 14 quarters since. The position peaked at $19.1M in Q4 2023. 475 funds tracked by Wall St. Rank hold BBIO as of Q2 2026.

  • Ikarian Capital held 57,417 shares of BridgeBio Pharma worth $4.28M as of Q2 2026.
  • Ikarian Capital sold 102,703 BridgeBio Pharma shares in Q2 2026, an estimated $7.19M.
  • BridgeBio Pharma made up 0.46% of Ikarian Capital's portfolio in Q2 2026, its #62 holding.
  • Ikarian Capital first reported a position in BridgeBio Pharma in Q1 2020 and has held it in 14 quarters since.
  • Ikarian Capital's BridgeBio Pharma position peaked at $19.1M in Q4 2023.
  • 475 funds tracked by Wall St. Rank held BridgeBio Pharma as of Q2 2026.

Based on Ikarian Capital's 13F filing for Q2 2026, filed 14 Aug 2026.